Elevated levels of oxidative stress biomarkers have been shown to associate with more aggressive behavior in malignancies. The aim of the present study was to determine the relationship between the expression of peroxiredoxins (Prx) and sulfiredoxin (Srx) in localized prostate cancer (PC) with clinicopathological parameters and outcome after radical prostatectomy (RP). Samples of 240 RP patients were analyzed for Prx1, 2, 5 and 6 and Srx expression by immunohistochemistry and the results were correlated with clinicopathological data, biochemical recurrence-free survival (BFS), prostate cancer-specific survival (PCS) and overall survival (OS). Augmented Prx2 and Prx6 expression was associated with several conventional prognostic factors. Increased Prx2 and Prx6 expression predicted for shortened BFS (p=0.027 and p=0.020) and worse OS (p=0.045 and p=0.033). In the multivariate analysis, Prx6 expression was an independent predictor of BFS (p=0.030). Elevated Prx6 expression associates with a worse prognosis after RP for clinically localized PC.